Avalo Therapeutics Inc宣布，其二期Lotus临床试验已成功达成主要研究终点。数据显示，在第16周的治疗评估节点，试验组患者呈现出显著临床应答，两组患者的应答率分别达到42.2%和42.9%。这一突破性进展标志着该公司在相关治疗领域取得重要里程碑。
Avalo Therapeutics Inc宣布，其二期Lotus临床试验已成功达成主要研究终点。数据显示，在第16周的治疗评估节点，试验组患者呈现出显著临床应答，两组患者的应答率分别达到42.2%和42.9%。这一突破性进展标志着该公司在相关治疗领域取得重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.